文献速递癫痫神经重症与神经感染

儿童难治性癫痫持续状态一线药物剂量研究

First-line medication dosing in pediatric refractory status epilepticus.
PubMed 文献 · Neurology · 2020-09-10

该回顾性研究纳入289例惊厥性难治性癫痫持续状态患儿,分析苯二氮䓬类(BZD)初始及总剂量与终止发作的关系。结果显示57.9%患儿初始剂量偏低,37.1%总剂量偏低;男性、较大年龄、无癫痫病史及延迟治疗与低总剂量相关,低总剂量降低发作终止可能性。

要点

  • 儿童难治性癫痫持续状态中BZD剂量常低于推荐,院外和院内均如此。
  • 男性、较大年龄、无癫痫病史及延迟治疗与低总BZD剂量相关。
  • 低总BZD剂量与发作终止可能性降低相关。

核心结论

  • 儿童难治性癫痫持续状态中BZD剂量低于推荐,且低总剂量与发作终止可能性降低相关。

研究设计与样本

  • 回顾性研究,前瞻性收集2011年6月至2019年1月收治的289例惊厥性难治性癫痫持续状态患儿数据。

主要发现

  • 278例(96.2%)以BZD为首选药物,其中161例(57.9%)初始剂量偏低。
  • 院外初始低剂量57/106例(53.8%),院内104/172例(60.5%)。
  • 低总BZD剂量与发作终止可能性降低相关(HR 0.7,95%CI 0.57-0.95)。

关键数值与推荐

  • 男性与低总BZD剂量相关(OR 2,95%CI 1.18-3.49;p=0.012)。
  • 较大年龄与低总BZD剂量相关(OR 1.1,95%CI 1.05-1.17;p<0.001)。
  • 无既往癫痫诊断与低总BZD剂量相关(OR 2.1,95%CI 1.23-3.69;p=0.008)。
  • 延迟BZD治疗与低总BZD剂量相关(OR 2.2,95%CI 1.24-3.94;p=0.007)。

临床怎么用

  • 临床应关注男性、较大年龄、无癫痫病史及延迟治疗的患儿,避免BZD剂量不足。
  • 确保BZD总剂量充足可能提高发作终止概率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify factors associated with low benzodiazepine (BZD) dosing in patients with refractory status epilepticus (RSE) and to assess the impact of BZD treatment variability on seizure cessation. METHODS: This was a retrospective study with prospectively collected data of children with convulsive RSE admitted between June 2011 and January 2019. We analyzed the initial and total BZD dose within 10 minutes of treatment initiation. We used logistic regression modeling to evaluate predictors of low BZD dosing and multivariate Cox regression analysis to assess the impact of low BZD dosing on time to seizure cessation. RESULTS: We included 289 patients (55.7% male) with a median age of 4.3 (1.3-9.5) years. BZDs were the initial medication in 278 (96.2%). Of those, 161 patients (57.9%) received a low initial dose. Low initial BZD doses occurred in both out-of-hospital (57 of 106; 53.8%) and in-hospital (104 of 172; 60.5%) settings. One hundred three patients (37.1%) received low total BZD dose. Male sex (odds ratio [OR] 2, 95% confidence interval [CI] 1.18-3.49; p = 0.012), older age (OR 1.1, 95% CI 1.05-1.17; p < 0.001), no prior diagnosis of epilepsy (OR 2.1, 95% CI 1.23-3.69; p = 0.008), and delayed BZD treatment (OR 2.2, 95% CI 1.24-3.94; p = 0.007) were associated with low total BZD dose. Patients who received low total BZD dosing were less likely to achieve seizure cessation (hazard ratio 0.7, 95% CI 0.57-0.95). CONCLUSION: BZD doses were lower than recommended in both out-of-hospital and in-hospital settings. Factors associated with low total BZD dose included male sex, older age, no prior epilepsy diagnosis, and delayed BZD treatment. Low total BZD dosing was associated with decreased likelihood of Seizure cessation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that patients with RSE who present with male sex, older age, no prior diagnosis of epilepsy, and delayed BZD treatment are more likely to receive low total BZD doses. This study provides Class III evidence that in pediatric RSE low total BZD dose decreases the likelihood of seizure cessation.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Vasquez A, Gaínza-Lein M, Abend NS, et al. First-line medication dosing in pediatric refractory status epilepticus. Neurology. 2020. PMID: 32913024. doi:10.1212/WNL.0000000000010828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。